Want to see GB:GNS full AI Analyst Report?
Genus plc (GNS) Share Price & Analysis
GNS Stock Chart & Stats
- Day’s Range
- GBX 2,284.00 - GBX 2,328.00
- 52-Week Range
- GBX 1,943.00 - GBX 3,220.00
- Previous Close
- GBX 2,286.00
- Volume
- 175.95K
- Average Volume (3M)
- 221.15K
- Market Cap
- GBP 1.48B
- Enterprise Value
- GBP 1.51B
- Total Cash (Recent Filing)
- GBP 43.70M
- Total Debt (Recent Filing)
- GBP 107.50M
- Price to Earnings (P/E)
- 5.3
- Beta
- 1.63
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- Nov 12, 2026
- Dividend Yield
- 1.43%
Bulls Say, Bears Say
Bulls Say
Balance Sheet Deleveraging
Material debt reduction and higher equity have strengthened Genus's financial resilience and lowered leverage risk. A healthier capital structure should preserve flexibility to fund research, support customers, pursue growth opportunities, and maintain shareholder returns through the next several quarters.
Operating Profit And Margin Growth
Broad-based operating profit and margin improvement indicates that Genus is converting revenue into earnings more efficiently across its businesses. Sustained productivity benefits, especially from ABS's improvement program, can support stronger earnings quality and investment capacity over time.
PRP Commercialization Progress
Regulatory progress for PRRS-resistant pig technology creates a potentially differentiated growth platform beyond Genus's established genetics portfolio. Additional approvals and early commercialization can build customer, supply, and data foundations for a new recurring revenue opportunity.
Bears Say
North American Disease Pressure
Livestock disease pressure is directly reducing customer production and royalty-linked revenue in North America. Management expects the headwind to continue into the first half of FY 2027, so recovery depends partly on normalization of operating conditions outside Genus's immediate control.
Weak Dairy Market Conditions
Persistent dairy-market weakness can constrain farmer spending and reduce demand for bovine genetics, limiting ABS volume growth even where Sexcel performs well. Continued depressed prices may therefore delay a broader recovery in the segment and make near-term growth more uneven.
Volatile Earnings Quality
The sharp profit increase despite lower revenue raises questions about how much of the improvement is repeatable operating performance. Earlier margin compression and inconsistent profitability make future earnings less predictable, requiring continued execution to demonstrate durable underlying progress.
Genus plc News
GNS FAQ
What was Genus plc’s price range in the past 12 months?
What is Genus plc’s market cap?
When is Genus plc’s upcoming earnings report date?
How were Genus plc’s earnings last quarter?
Is Genus plc overvalued?
Does Genus plc pay dividends?
What is Genus plc’s EPS estimate?
How many shares outstanding does Genus plc have?
What happened to Genus plc’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Genus plc?
What is the TipRanks Smart Score and how is it calculated?
Genus plc Stock Smart Score
Company Description
Genus plc
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Genus Research and Development. Under its PIC brand, the company provides breeding stock, including sows, boars, and semen, to develop pigs with specific characteristics optimized for pork production. Similarly, for cattle, its ABS, Genus, and Bovec brands offer bull semen and embryos designed to produce calves with advantageous traits for either milk or beef output. Farmers also benefit from a range of specialized technical services, such as semen sexing and reproductive solutions. Genus plc is also strategically collaborating with Beijing Capital Agribusiness Co. Ltd on the research, development, and regulatory approval of porcine reproductive and respiratory syndrome virus (PRRSV)-resistant pigs in China. The company was established in 1994 and is based in Basingstoke, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jorgen Kokke
- Employees
- 2,921
- Website
- www.genusplc.com
- Address
- Matrix House, Basingstoke, HM, RG21 4FF, GB
Genus plc (GNS) Earnings & Revenues
GNS Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. Management reported substantial adjusted profit, EPS, free cash flow, margin, leverage, and return-on-capital improvements, alongside strong PIC China and ABS performance, PRP regulatory progress, capital returns, and a moderately higher FY 2027 profit outlook. These strengths were partly offset by disease pressure in North America, weak pork and dairy market conditions, expected moderation in Brazil and lower FY 2027 free cash flow, but the stated outlook remained for resilient underlying growth.
View all GB:GNS earnings summariesGNS Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 5 | 4 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 9 | 0 | 3 |